참고문헌
- Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38. https://doi.org/10.1016/j.jacc.2009.09.009
- Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 2004;19:575-81.
- Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 2004;64:1-12. https://doi.org/10.1111/j.0001-2815.2004.00278.x
- Zanetta JP, Badache A, Maschke S, Marschal P, Kuchler S. Carbohydrates and soluble lectins in the regulation of cell adhesion and proliferation. Histol Histopathol 1994;9:385-412.
- Rabinovich GA, Toscano MA, Ilarregui JM, Rubinstein N. Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj J 2004;19:565-73.
- Moiseeva EP, Javed Q, Spring EL, de Bono DP. Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 2000;45:493-502. https://doi.org/10.1016/S0008-6363(99)00276-X
- Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999;1473:172-85. https://doi.org/10.1016/S0304-4165(99)00177-4
- Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-64. https://doi.org/10.4049/jimmunol.165.4.2156
- Iacobini C, Menini S, Ricci C, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptormediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29:831-6. https://doi.org/10.1161/ATVBAHA.109.186791
- Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905-13. https://doi.org/10.1177/039463201102400409
- Kircher MF, Grimm J, Swirski FK, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008;117:388-95. https://doi.org/10.1161/CIRCULATIONAHA.107.719765
- Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002;23:313-20. https://doi.org/10.1016/S1471-4906(02)02232-9
- Chen HY, Fermin A, Vardhana S, et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A 2009;106:14496-501. https://doi.org/10.1073/pnas.0903497106
- MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008;180:2650-8. https://doi.org/10.4049/jimmunol.180.4.2650
- Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 2010;185:7037-46. https://doi.org/10.4049/jimmunol.1000154
- Forsman H, Islander U, Andreasson E, et al. Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum 2011;63:445-54. https://doi.org/10.1002/art.30118
- Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998;152:1199-208.
- Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004;429:72-5. https://doi.org/10.1038/nature02502
- Chellan B, Narayani J, Appukuttan PS. Galectin-1, an endogenous lectin produced by arterial cells, binds lipoprotein(a) [Lp(a)] in situ: relevance to atherogenesis. Exp Mol Pathol 2007;83:399-404. https://doi.org/10.1016/j.yexmp.2007.04.004
- Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008;172:247-55. https://doi.org/10.2353/ajpath.2008.070348
- Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010;5:e8852. https://doi.org/10.1371/journal.pone.0008852
- Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010;1183:158-82. https://doi.org/10.1111/j.1749-6632.2009.05131.x
- Romaniuk MA, Tribulatti MV, Cattaneo V, et al. Human platelets express and are activated by galectin-8. Biochem J 2010;432:535-47. https://doi.org/10.1042/BJ20100538
- Liu FT, Yang RY, Hsu DK. Galectins in acute and chronic inflammation. Ann N Y Acad Sci 2012;1253:80-91. https://doi.org/10.1111/j.1749-6632.2011.06386.x
- Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 1998;430:307-11. https://doi.org/10.1016/S0014-5793(98)00683-8
- Moiseeva EP, Williams B, Samani NJ. Galectin 1 inhibits incorporation of vitronectin and chondroitin sulfate B into the extracellular matrix of human vascular smooth muscle cells. Biochim Biophys Acta 2003;1619:125-32. https://doi.org/10.1016/S0304-4165(02)00447-6
- Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995;147:1016-28.
- Puato M, Faggin E, Rattazzi M, et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatinbased regimen in patients undergoing carotid endarterectomy. Stroke 2010;41:1163-8. https://doi.org/10.1161/STROKEAHA.110.580811
Cited by
- Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naive patients with hypertension with atherosclerosis vol.64, pp.7, 2013, https://doi.org/10.1136/jim-2016-000092
- Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/8696543
- Serum Galectin-3 and Poor Outcomes Among Patients With Acute Ischemic Stroke vol.49, pp.1, 2013, https://doi.org/10.1161/strokeaha.117.019084
- Therapeutic effects of simvastatin on Galectin-3 and oxidative stress parameters in endotoxemic lung tissue vol.38, pp.3, 2013, https://doi.org/10.1042/bsr20180308
- Galectin-1 Restricts Vascular Smooth Muscle Cell Motility Via Modulating Adhesion Force and Focal Adhesion Dynamics vol.8, pp.None, 2013, https://doi.org/10.1038/s41598-018-29843-3
- Galectin-3 Is a Potential Mediator for Atherosclerosis vol.2020, pp.None, 2013, https://doi.org/10.1155/2020/5284728
- Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study vol.9, pp.6, 2020, https://doi.org/10.3390/jcm9061640
- Value of Galectin-3 in Acute Myocardial Infarction vol.20, pp.4, 2013, https://doi.org/10.1007/s40256-019-00387-9
- Galectin-1 is associated with the severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography vol.10, pp.1, 2020, https://doi.org/10.1038/s41598-020-77804-6
- The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases vol.12, pp.1, 2022, https://doi.org/10.3390/biom12010046